IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
Saved in:
| Title: | IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. |
|---|---|
| Authors: | Martin-Broto J; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Strauss SJ; Department of Medical Oncology, University College London Hospital, London, UK., Palmerini E; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.; Department of Medical Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Valverde C; Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain., Sebio A; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain., Redondo A; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Stacchiotti S; Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy., Grignani G; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy., Aliberti S; Medical Oncology Department, Candiolo Cancer Institute, Fondazione Piemontese per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Italy., Diaz-Beveridge R; Department of Medical Oncology, University Hospital La Fe, Valencia, Spain., Billalabeitia EG; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain., Cruz J; Department of Medical Oncology, Canarias University Hospital, La Laguna, Spain., Carrasco-Garcia I; Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain., Ibrahim T; Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy., Diaz-Martin J; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain., Salguero-Aranda C; Institute of Biomedicine of Seville, Spanish National Research Council-University of Seville, Department of Pathology, University Hospital Virgen del Rocio, Seville, Spain.; Biomedical Research Networking Center in Cancer (CIBERONC), Carlos III Health Institute, Madrid, Spain., Gutierrez A; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain., Mayordomo-Aranda E; Department of Pathology, University Hospital La Fe, Valencia, Spain., Ramos R; Department of Pathology, University Hospital Son Espases, Palma de Mallorca, Spain., Merino J; Department of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain., Collini P; Advanced Diagnostic Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy., Tirabosco R; Department of Pathology, University College London Hospital, London, UK., Bague S; Department of Pathology, Sant Pau Hospital, Barcelona, Spain., Romagosa C; Department of Pathology, University Hospital Vall d'Hebron, Barcelona, Spain., Carrera MA; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Ledesma P; Sofpromed Investigación Clínica, Palma de Mallorca, Spain., Hindi N; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain., Moura DS; University Hospital General de Villalba, Madrid, Spain.; Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain. |
| Source: | Cancer communications (London, England) [Cancer Commun (Lond)] 2026 Mar 12; Vol. 46, pp. 0015. Date of Electronic Publication: 2026 Mar 12 (Print Publication: 2026). |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: eCollection Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
